Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases

Figure 3 Comparison of various conditioning regimens in multiple myeloma. A: Comparison of overall survival between busulfan 0.8 mg/kg along with etoposide IV 400 mg/m² plus cyclophosphamide 50 mg/kg (BVC), melphalan (MEL) given at a dose of 100 mg/m²/d (HDM), high dose MEL 200 mg/m² (MEL 200), and low dose MEL given at a dose of 140 mg (MEL 140); B: Comparison of progression free survival between BVC, HDM, MEL 200, and MEL 140.